# Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.

> **NCT04710732** · PHASE4 · TERMINATED · sponsor: **Pirogov Russian National Research Medical University** · enrollment: 9 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Standard Enoxaparin 40 mg once-daily before randomization
- **DRUG:** Standard Enoxaparin 40 mg once-daily after randomization
- **DRUG:** Escalated Enoxaparin 30 mg twice-daily after randomization
- **DEVICE:** Anti-embolic elastic compression stockings
- **DIAGNOSTIC_TEST:** Thrombodynamic test (TD)

## Key facts

- **NCT ID:** NCT04710732
- **Lead sponsor:** Pirogov Russian National Research Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of the eligible patients
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04710732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04710732, "Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04710732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*